| Vaxart Inc (VXRT) | |||
|---|---|---|---|
| 0.7147 0.001 (0.2%) | 04-30 16:00 | ||
| Open: | 0.75 | Pre. Close: | 0.7133 |
| High: | 0.7626 | Low: | 0.68 |
| Volume: | 1,965,880 | Market Cap: | 126(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 1.30 One year: 1.65 |
| Support: | Support1: 0.63 Support2: 0.53 |
| Resistance: | Resistance1: 1.11 Resistance2: 1.41 |
| Pivot: | 0.82  |
| Moving Averages: | MA(5): 0.70 MA(20): 0.89 MA(100): 0.95  MA(250): 0.87 |
| MACD: | MACD(12,26): -0.12 Signal(12,26,9): -0.11 |
| %K %D: | %K(14,3): 17.76 %D(3): 12.64 |
| RSI: | RSI(14): 27.16 |
| 52-Week: | High: 1.59 Low: 0.53 Change(%): -13.9 |
| Average Vol(K): | 3-Month: 1707 10-Days: 1399 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.761 - 0.764 | 0.764 - 0.767 |
| Low: | 0.673 - 0.676 | 0.676 - 0.679 |
| Close: | 0.705 - 0.71 | 0.71 - 0.716 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VXRT ] has closed above bottom band by 27.8%. Bollinger Bands are 38.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 173.86 |
| % Held by Insiders | 156960000.00 |
| % Held by Institutions | 0.97 |
| Shares Short (K) | 13710 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -74720000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | -520.80 |
| Return on Assets (ttm) | -42.4 |
| Return on Equity (ttm) | -97.9 |
| Qtrly Rev. Growth | 14.0 |
| Gross Profit (p.s.) | 1160.714 |
| Sales Per Share | 13178571.000 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -0.57 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -70.45 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow | 1.05 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 17190000.000 |
